{"transactions":[{"id":2016455,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-14T14:05:17.000Z","date":"2022-12-27","kind":"gift","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Daughter"},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001140361-23-006840","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036123006840/form5.xml","form_type":"5"}},{"id":2016454,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-14T14:05:17.000Z","date":"2022-12-27","kind":"gift","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":296045,"source":{"system":"sec-edgar","filing":"0001140361-23-006840","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036123006840/form5.xml","form_type":"5"}},{"id":2016453,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-14T14:05:17.000Z","date":"2022-12-23","kind":"gift","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":396045,"source":{"system":"sec-edgar","filing":"0001140361-23-006840","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036123006840/form5.xml","form_type":"5"}},{"id":2055700,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-12T18:08:04.000Z","date":"2023-01-10","kind":"grant","acquired":true,"shares":201683,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest with respect to 50,420 shares on January 10, 2024, with the balance vesting quarterly in twelve equal installments thereafter."}],"balance_after":201683,"derivative":{"exercise_price":3.5,"expiration_date":"2033-01-09","underlying":"Common Stock","underlying_shares":201683},"source":{"system":"sec-edgar","filing":"0001140361-23-001520","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036123001520/form4.xml","form_type":"4"}},{"id":2055699,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-12T18:08:04.000Z","date":"2023-01-10","kind":"grant","acquired":true,"shares":134456,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of January 10, 2023."}],"balance_after":430501,"source":{"system":"sec-edgar","filing":"0001140361-23-001520","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036123001520/form4.xml","form_type":"4"}},{"id":2163204,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Series B Warrant (right to buy)","published_at":"2022-09-08T16:01:37.000Z","date":"2022-09-06","kind":"other","acquired":false,"shares":1023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The expiration date of the Series B Warrants occurred on the later of (x) the Reservation Date (as defined in the Series B Warrants) and (y) the date on which the Series B Warrant has been exercised in full."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"exercise_date":"2020-11-19","expiration_date":"2022-09-07","underlying":"Common Stock","underlying_shares":1023},"source":{"system":"sec-edgar","filing":"0001140361-22-032758","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036122032758/form4.xml","form_type":"4"}},{"id":2163203,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-08T16:01:37.000Z","date":"2022-09-06","kind":"other","acquired":true,"shares":1023,"price":0.0001,"value":0.1023,"ownership":{"direct":true},"balance_after":426045,"source":{"system":"sec-edgar","filing":"0001140361-22-032758","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036122032758/form4.xml","form_type":"4"}},{"id":2260080,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-05-23T16:58:51.000Z","date":"2022-05-20","kind":"purchase","acquired":true,"shares":12500,"price":2.024,"value":25300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price represents the weighted average price of the multiple transactions reported on this line.  The shares were purchased at prices ranging from $2.015 to $2.025.  Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price."}],"balance_after":425022,"source":{"system":"sec-edgar","filing":"0001140361-22-020274","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036122020274/form4.xml","form_type":"4"}},{"id":2260079,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-05-23T16:58:51.000Z","date":"2022-05-19","kind":"purchase","acquired":true,"shares":12500,"price":2.0703,"value":25878.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents the weighted average price of the multiple transactions reported on this line.  The shares were purchased at prices ranging from $2.045 to $2.10.  Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price."}],"balance_after":412522,"source":{"system":"sec-edgar","filing":"0001140361-22-020274","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036122020274/form4.xml","form_type":"4"}},{"id":2419291,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-01T16:26:43.000Z","date":"2022-01-28","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest with respect to 50,000 shares on January 28, 2023, and then with respect to 4,166 shares on the last day of each month from February 2023 through December 2025 and with respect to 4,190 shares at the end of January 2026."}],"balance_after":200000,"derivative":{"exercise_price":2.9,"expiration_date":"2032-01-27","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-22-003495","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036122003495/form4.xml","form_type":"4"}},{"id":2966223,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Series B Warrant (right to buy)","published_at":"2020-11-25T19:26:07.000Z","date":"2020-11-19","kind":"purchase","acquired":true,"shares":2046,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Subject to adjustment based on certain price reset provisions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $65,000."}],"balance_after":2046,"derivative":{"exercise_price":0.0001,"exercise_date":"2020-11-19","expiration_date":"2022-01-28","underlying":"Common Stock","underlying_shares":2046},"source":{"system":"sec-edgar","filing":"0001140361-20-026646","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036120026646/form4.xml","form_type":"4"}},{"id":2966222,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Series A Warrant (right to buy)","published_at":"2020-11-25T19:26:07.000Z","date":"2020-11-19","kind":"purchase","acquired":true,"shares":17413,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Subject to adjustment based on certain price reset provisions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $65,000."}],"balance_after":17413,"derivative":{"exercise_price":4.4795,"exercise_date":"2020-11-19","expiration_date":"2025-11-19","underlying":"Common Stock","underlying_shares":17413},"source":{"system":"sec-edgar","filing":"0001140361-20-026646","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036120026646/form4.xml","form_type":"4"}},{"id":2966221,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-25T19:26:07.000Z","date":"2020-11-19","kind":"purchase","acquired":true,"shares":11524,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $65,000."}],"balance_after":800044,"source":{"system":"sec-edgar","filing":"0001140361-20-026646","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036120026646/form4.xml","form_type":"4"}},{"id":2981394,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-11-13T17:17:11.000Z","date":"2020-11-11","kind":"grant","acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"2,700 shares vest each month-end from November 2020 through September 2024.  The balance vests in October 2024."}],"balance_after":130000,"derivative":{"exercise_price":4.05,"expiration_date":"2030-11-11","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001140361-20-025546","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000114036120025546/form4.xml","form_type":"4"}},{"id":2988301,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-11-09T17:42:16.000Z","date":"2020-11-05","kind":"grant","acquired":true,"shares":158475,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. (\"Rexahn\") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. (\"Ocuphire\"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"19,017 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2021, subject to continued service."}],"balance_after":158475,"derivative":{"exercise_price":1.21,"expiration_date":"2029-12-27","underlying":"Common Stock","underlying_shares":158475},"source":{"system":"sec-edgar","filing":"0001596771-20-000109","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000159677120000109/primary_doc.xml","form_type":"4"}},{"id":2988300,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-11-09T17:42:16.000Z","date":"2020-11-05","kind":"grant","acquired":true,"shares":178284,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. (\"Rexahn\") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. (\"Ocuphire\"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":178284,"derivative":{"exercise_price":0.9,"expiration_date":"2028-10-01","underlying":"Common Stock","underlying_shares":178284},"source":{"system":"sec-edgar","filing":"0001596771-20-000109","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000159677120000109/primary_doc.xml","form_type":"4"}},{"id":2988299,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-09T17:42:16.000Z","date":"2020-11-05","kind":"grant","acquired":true,"shares":788520,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. (\"Rexahn\") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. (\"Ocuphire\"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc."}],"balance_after":788520,"source":{"system":"sec-edgar","filing":"0001596771-20-000109","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000159677120000109/primary_doc.xml","form_type":"4"}},{"id":3674446,"issuer":{"id":7702,"kind":"organization","name":"BIOVIE INC."},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-05T15:37:46.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":200000,"price":0.035,"value":7000.0,"ownership":{"direct":true},"balance_after":813636,"source":{"system":"sec-edgar","filing":"0001674006-19-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000167400619000001/primary_doc.xml","form_type":"4"}},{"id":3844829,"issuer":{"id":7702,"kind":"organization","name":"BIOVIE INC."},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2018-08-14T18:14:40.000Z","date":"2018-04-30","kind":"grant","acquired":true,"shares":150000,"price":0.024,"value":3600.0,"ownership":{"direct":true},"balance_after":613636,"source":{"system":"sec-edgar","filing":"0001674006-18-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000167400618000003/primary_doc.xml","form_type":"4"}},{"id":3844828,"issuer":{"id":7702,"kind":"organization","name":"BIOVIE INC."},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2018-08-14T18:14:40.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":200000,"price":0.15,"value":30000.0,"ownership":{"direct":true},"balance_after":463636,"source":{"system":"sec-edgar","filing":"0001674006-18-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000167400618000003/primary_doc.xml","form_type":"4"}},{"id":4540376,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-11-29T16:29:18.000Z","date":"2016-11-25","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted an option to purchase 600,000 shares of common stock effective August 4, 2016.  360,000 of the shares underlying the option award were immediately earned on the date of the grant, 120,000 shares underlying the option award were earned on September 30, 2016 following the initiation of the Company's first clinical trial and 120,000 shares underlying the option award are earned upon the initiation of the Company's second clinical trial.  The Company has initiated its second clinical trial, so the 120,000 shares underlying the option award that were subject to the initiation of the Company's second clinical trial have been earned."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 48 equal consecutive monthly increments, so that all of the shares will be vested on the fourth anniversary of the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person was granted an option to purchase 600,000 shares of common stock effective August 4, 2016.  360,000 of the shares underlying the option award were immediately earned on the date of the grant, 120,000 shares underlying the option award were earned on September 30, 2016 following the initiation of the Company's first clinical trial and 120,000 shares underlying the option award are earned upon the initiation of the Company's second clinical trial.  The Company has initiated its second clinical trial, so the 120,000 shares underlying the option award that were subject to the initiation of the Company's second clinical trial have been earned."}],"balance_after":600000,"derivative":{"exercise_price":10,"expiration_date":"2026-08-03","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001596771-16-000166","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000159677116000166/primary_doc.xml","form_type":"4"}},{"id":4590246,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":116917,"kind":"person","name":"Sooch Mina","position":1,"cik":"0001674006","reported_name":"Sooch Mina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-10-03T16:32:03.000Z","date":"2016-09-30","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted an option to purchase 600,000 shares of common stock effective August 4, 2016. 360,000 of the shares underlying the option award were immediately earned on the date of grant, 120,000 shares underlying the option award are earned upon the initiation of the Company's first clinical trial and 120,000 shares underlying the option award are earned upon the initiation of the Company's second clinical trial. The Company has initiated its first clinical trial, so the 120,000 shares underlying the option award that were subject to the initiation of the Company's first clinical trial have been earned."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 48 equal consecutive monthly increments, so that all of the shares will be vested on the fourth anniversary of the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person was granted an option to purchase 600,000 shares of common stock effective August 4, 2016. 360,000 of the shares underlying the option award were immediately earned on the date of grant, 120,000 shares underlying the option award are earned upon the initiation of the Company's first clinical trial and 120,000 shares underlying the option award are earned upon the initiation of the Company's second clinical trial. The Company has initiated its first clinical trial, so the 120,000 shares underlying the option award that were subject to the initiation of the Company's first clinical trial have been earned."}],"balance_after":480000,"derivative":{"exercise_price":10,"expiration_date":"2026-08-03","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001596771-16-000157","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674006/000159677116000157/primary_doc.xml","form_type":"4"}}]}